DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 38.7% in March

DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 366,400 shares, an increase of 38.7% from the March 15th total of 264,200 shares. Based on an average trading volume of 90,200 shares, the days-to-cover ratio is currently 4.1 days. Approximately 0.9% of the company's stock are sold short.

DiaMedica Therapeutics Stock Up 3.4 %

DMAC stock traded up $0.13 during midday trading on Wednesday, hitting $4.01. 41,201 shares of the company traded hands, compared to its average volume of 74,388. The business has a 50 day simple moving average of $4.89 and a 200-day simple moving average of $5.04. DiaMedica Therapeutics has a twelve month low of $2.14 and a twelve month high of $6.82. The stock has a market capitalization of $171.85 million, a price-to-earnings ratio of -7.16 and a beta of 1.50.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last announced its earnings results on Monday, March 17th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Equities research analysts forecast that DiaMedica Therapeutics will post -0.59 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright increased their price target on shares of DiaMedica Therapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, March 19th.

Institutional Trading of DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Paragon Associates & Paragon Associates II Joint Venture grew its stake in shares of DiaMedica Therapeutics by 6.7% in the fourth quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 514,784 shares of the company's stock worth $2,795,000 after acquiring an additional 32,170 shares during the last quarter. Susquehanna International Group LLP grew its position in DiaMedica Therapeutics by 269.5% in the 4th quarter. Susquehanna International Group LLP now owns 374,845 shares of the company's stock worth $2,035,000 after purchasing an additional 273,395 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of DiaMedica Therapeutics by 29.6% during the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company's stock worth $1,286,000 after purchasing an additional 70,070 shares during the period. Northern Trust Corp raised its position in shares of DiaMedica Therapeutics by 49.8% during the fourth quarter. Northern Trust Corp now owns 180,192 shares of the company's stock valued at $978,000 after buying an additional 59,902 shares during the last quarter. Finally, LPL Financial LLC lifted its stake in shares of DiaMedica Therapeutics by 8.2% in the fourth quarter. LPL Financial LLC now owns 152,000 shares of the company's stock valued at $825,000 after buying an additional 11,500 shares during the period. Institutional investors and hedge funds own 10.12% of the company's stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.